APA (7th ed.) Citation

Abo Nahas, H. H., Al-Dakhil, A., Mohamed, D. I., Yousef, T. A., Almaaty, A. H. A., El-Deen, I. M., . . . Saied, E. M. (2026). Rebamipide Reprograms Hepatic Networks to Prevent and Reverse Metabolic-Dysfunction-Associated Steatotic Liver Disease: Multi-Omics Insights and Histological Validation. Pharmaceuticals (14248247), 19(4), 559. https://doi.org/10.3390/ph19040559

Chicago Style (17th ed.) Citation

Abo Nahas, Hebatallah H., Abdullah Al-Dakhil, Doaa I. Mohamed, Tarek A. Yousef, Ali H. Abu Almaaty, Ibrahium M. El-Deen, Hatem Adel M. Sembawa, and Essa M. Saied. "Rebamipide Reprograms Hepatic Networks to Prevent and Reverse Metabolic-Dysfunction-Associated Steatotic Liver Disease: Multi-Omics Insights and Histological Validation." Pharmaceuticals (14248247) 19, no. 4 (2026): 559. https://doi.org/10.3390/ph19040559.

MLA (9th ed.) Citation

Abo Nahas, Hebatallah H., et al. "Rebamipide Reprograms Hepatic Networks to Prevent and Reverse Metabolic-Dysfunction-Associated Steatotic Liver Disease: Multi-Omics Insights and Histological Validation." Pharmaceuticals (14248247), vol. 19, no. 4, 2026, p. 559, https://doi.org/10.3390/ph19040559.